Table 1.

Clinical and Biochemical Features of Five Patients Presenting with Cyanotic Congenital Heart Disease and Pheochromocytomas or Paragangliomas (PPGL), with EPAS1 Mutation Status.^*

Patient No. and Age	Description of Cyanotic Congenital Heart Disease and Treatment	Features at PPGL Diagnosis			Catecholamines†	PPGL Location and Size	EPAS1 Genotype
		Sao2‡ %	Hematocrit %	Symptoms			Tumor	Germline
1, 48 yr	Tricuspid and pulmonary atresia, ASD, and VSD Treatment: Potts shunt at 5 mo of age; right BTS at 5 yr	79	64.4	Paroxysmal atrial fibrillation, diaphoresis, hypertension, anxiety, palpable neck mass	P-NMN, 14×; P-MN, 2×	Left adrenal PHEO, 3.0cm×4.0 cm; right carotid body PGL, 1.2 cmx 1.7 cm	c,1591C→T, p.Pro531Ser in PHEO; WT in PGL	NA§
2, 13 yr	Pulmonary atresia, double-outlet right ventricle, common atrioventricular canal defect, ASD, and VSD Treatment: left BTS at 3 days of age; central shunt at 7 yr; Kawashima, left pulmonary arterioplasty, atrioventricular valvuloplasty, and central shunt closure at 17 yr	85	55.0	Hypertension, diaphoresis, palpitations, dyspnea	P-NMN, 5×; P-MN, normal	Left adrenal PHEO, 6.4cm×5 cm	c,1588G→C, p.Ala530Pro	WT
3, 23 yr	Tricuspid atresia with “normally related greater arteries” and pulmonary stenosis and bilateral SVC Treatment: Left BTS at 4 mo of age; bidirectional Glenn shunt at 2 yr; lateral tunnel fenestrated Fontan procedure at 3 yr; fenestration-device closure at 16 yr; ICD for cardiac arrest at 20 yr	92	47.3	Hypertension, diaphoresis	P-NMN, ll×; P-MN, normal	Abdominal periaortic PGL, 2.9cm×2.7 cm	c,1592C→G, p.Pro531Arg	WT
4, 21 yr	Heterotaxy syndrome with polysplenia, double-outlet right ventricle, right dominant atrioventricular canal defect, hypoplastic left ventricle, interrupted IVC, and AVM in left lung Treatment: pulmonary-artery banding at 2 wk of age; bilateral Glenn shunt and fenestrated intraatrial baffling of hepatic veins to right pulmonary artery at 2 yr; pulmonary valvectomy and closure of baffle fenestration at 4yr	77	50.9	Syncope, diaphoresis, dyspnea, chest pain, headaches	P-NMN, 30x; P-MN, normal	Right adrenal PHEO, 4.3cmx4.0cm	c. 1591C->T, p.Pro531Ser	WT
5,54 yr	Tetralogy of Fallot with pulmonary stenosis Treatment: Potts shunt at 8 mo of age; intracardiac repair at 9 yr; aortobifemoral bypass for PAD at 38 yr; PVR, tricuspid-valve repair, and left pulmonary arterioplasty at 48 yr; ICD for NSVT at 52 yr	92	39.7	Hypertension, diaphoresis, palpitations	P-NMN, 23×; P-MN, <2×	Abdominal periaortic PGL, 6.3cm×5.8 cm	WT	WT

^*Patients 1 and 5 were white women, Patient 2 a Hispanic girl, Patient 3 an Asian man, and Patient 4 a Hispanic woman; race was reported by the patients (Patients 1, 3, 4, and 5) or determined by the investigators (Patient 2). All five patients had had hypoxemia for the duration of their lives. Immunohistochemical testing for succinate dehydrogenase complex subunit A and subunit B was positive in all patients, except that the test for succinate dehydrogenase complex subunit B was only weakly positive in Patient 5. Full details regarding the clinical and biochemical features of these patients are provided in Table S1 in the Supplementary Appendix. ASD denotes atrial septal defect, AVM arteriovenous malformations, BTS Blalock–Taussig shunt, ICD implantable cardioverter-defibrillator, IVC inferior vena cava, NA not available, NSVT nonsustained ventricular tachycardia, PAD peripheral-artery disease, PGL paraganglioma, PHEO pheochromocytoma, PVR pulmonary-valve replacement, SVC superior vena cava, VSD ventricular septal defect, and WT wild type.

^†Plasma catecholamine levels of normetanephrines (P-NMN) and metanephrines (P-MN) were assessed before PHEO or PGL surgery. Data show the value as a factor above the upper boundary of the normal range (112 pg per milliliter for normetanephrines and 61 pg per milliliter for metanephrines).

^‡Shown is the arterial oxygen saturation (Sao₂) level at diagnosis. Historical data were available for three patients: Patient 3 had had an Sao₂ of approximately 70% at younger than 4 months of age, 85% at 4 months to 3 years of age, and 92 to 94% at 3 to 23 years of age; Patient 4, a history of Sao₂ values ranging from 70 to 77% throughout follow-up; and Patient 5, an Sao₂ of approximately 80% at younger than 9 years of age and 92% at 9 to 54 years of age.

^§The existence of two separate tumors with distinct EPAS1 genotypes in this patient served as evidence of the somatic status of the EPAS1 mutation in PHEO.